JB Chemicals & Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
No analysis found
We don't have this information yet. Please check back later.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 1950.00 | 40.76 | 467870.32 | 0.82 | 2709.66 | 25.80 | 14611.79 | 12.76 | 19.11 | 26.97 |
| Divi's Laboratories Ltd. | 7319.75 | 75.67 | 194316.36 | 0.41 | 751.00 | 13.44 | 2831.00 | 9.52 | 21.51 | 32.99 |
| Torrent Pharmaceuticals Ltd. | 5002.75 | 78.26 | 169315.79 | 0.76 | 364.00 | -26.91 | 4197.00 | 41.84 | 19.27 | 32.31 |
| Cipla Ltd. | 1429.45 | 29.77 | 115477.45 | 0.91 | 542.51 | -55.32 | 6541.20 | -2.80 | 16.00 | 15.13 |
| Zydus Lifesciences Ltd. | 1153.50 | 22.83 | 115062.07 | 0.09 | 1341.00 | 7.82 | 7587.00 | 16.22 | 21.39 | 25.16 |
| Lupin Ltd. | 2500.05 | 21.44 | 114311.01 | 0.72 | 1468.67 | 87.72 | 7474.66 | 31.89 | 28.86 | 33.25 |
| Mankind Pharma Ltd. | 2545.00 | 54.95 | 105107.48 | 0.00 | 559.42 | 31.74 | 3442.93 | 11.81 | 13.24 | 27.10 |
| Dr. Reddy's Laboratories Ltd. | 1223.90 | 24.35 | 102155.97 | 0.65 | 221.30 | -86.05 | 7546.40 | -11.51 | 13.75 | 5.13 |
| Aurobindo Pharma Ltd. | 1548.10 | 25.42 | 89074.25 | 0.26 | 920.84 | 1.99 | 8853.34 | 5.62 | 14.39 | 19.77 |
| Laurus Labs Ltd. | 1557.60 | 94.68 | 84149.28 | 0.13 | 282.09 | 21.19 | 1811.57 | 5.31 | 18.20 | 28.28 |
| Biocon Ltd. | 440.70 | 186.26 | 71820.62 | 0.11 | 198.60 | -56.77 | 4516.60 | 2.25 | 3.26 | 22.59 |
| Alkem Laboratories Ltd. | 5703.50 | 29.63 | 68193.90 | 0.93 | 251.11 | -22.11 | 3603.32 | 14.62 | 21.56 | 14.34 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,004 | 1,001 | 963 | 949 | 1,094 | 1,085 | 1,065 | 904 |
| 724 | 730 | 709 | 723 | 793 | 775 | 769 | 703 | |
| Operating Profit | 280 | 271 | 255 | 226 | 301 | 310 | 296 | 201 |
| OPM % | 28% | 27% | 26% | 24% | 28% | 29% | 28% | 22% |
| 6 | 10 | 8 | 14 | 15 | 15 | 18 | -15 | |
| Interest | 6 | 2 | 3 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 41 | 42 | 42 | 46 | 43 | 44 | 45 | 50 |
| Profit before tax | 240 | 237 | 218 | 193 | 272 | 279 | 267 | 135 |
| Tax % | 26% | 26% | 25% | 25% | 25% | 26% | 26% | 25% |
| Net Profit | 177 | 175 | 162 | 146 | 202 | 208 | 198 | 101 |
| EPS in Rs | 11.39 | 11.24 | 10.45 | 9.36 | 12.96 | 13.27 | 12.63 | 6.31 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 3,29,864 | 3,72,292 | 3,88,989 |
| 2,42,157 | 2,70,765 | 2,83,794 | |
| Operating Profit | 87,708 | 1,01,527 | 1,05,195 |
| OPM % | 27% | 27% | 27% |
| 3,702 | 3,740 | 5,923 | |
| Interest | 4,052 | 912 | 459 |
| Depreciation | 13,524 | 16,645 | 17,669 |
| Profit before tax | 73,834 | 87,711 | 90,273 |
| Tax % | 26% | 26% | 25% |
| Net Profit | 54,336 | 65,254 | 67,410 |
| EPS in Rs | 35.07 | 42.00 | 42.91 |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- Last Year:
- 19%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1,552 | 1,557 | 1,606 |
| Reserves | 2,73,090 | 3,19,360 | 4,02,165 |
| Borrowings | 34,180 | 0 | 0 |
| 1,35,438 | 1,54,297 | 1,50,402 | |
| Total Liabilities | 4,44,260 | 4,75,214 | 5,54,173 |
| 1,92,542 | 1,88,329 | 1,79,645 | |
| CWIP | 7,606 | 6,170 | 7,380 |
| 53,123 | 48,796 | 90,781 | |
| 1,90,988 | 2,31,918 | 2,76,367 | |
| Total Assets | 4,44,260 | 4,75,214 | 5,54,173 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 78,903 | 88,403 | 64,489 | |
| Cash from Investing Activity | -41,245 | -28,993 | -58,721 |
| Cash from Financing Activity | -37,408 | -57,427 | -10,768 |
| Net Cash Flow | 250 | 1,984 | -5,000 |
| CFO/OP | 86% | 84% | 58% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 61 | 71 | 72 |
| Inventory Days | 45 | 48 | 54 |
| Days Payable | 91 | 104 | 113 |
| Cash Conversion Cycle | 16 | 14 | 14 |
| ROCE % | 25 | 27 | 24 |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-07-13 - Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited shall be suspended w.e.f. July 17, 2026 (i.e., closing hours of trading on July 16, 2026) on account of the Scheme of Amalgamation.
2026-07-08 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
2026-07-07 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-07-07 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 17-Jul-2026.
2026-07-07 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
2026-07-06 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
2026-07-01 - Torrent Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2026-06-30 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-06-30 - JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Change in Senior Management Personnel
News
Recent coverage and analyst commentary for JBCHEPHARM
Loading news…
AI Stock Analyst
JB Chemicals & Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account